Drug Profile
Bevacizumab biosimilar - Boehringer Ingelheim
Alternative Names: BI 695502Latest Information Update: 02 Dec 2022
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim
- Class Antineoplastics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Colorectal cancer; Non-small cell lung cancer
- No development reported Cancer
Most Recent Events
- 31 May 2022 No development reported - Phase-III for Colorectal cancer (Combination therapy, First-line therapy, Metastatic disease) in Ukraine (IV) (Boehringer Ingelheim Pipeline, May 2022)
- 31 May 2022 No development reported - Phase-III for Colorectal cancer (Combination therapy, First-line therapy, Metastatic disease) in USA (IV) (Boehringer Ingelheim Pipeline, May 2022)
- 31 May 2022 No development reported - Phase-III for Non-small cell lung cancer (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease, Recurrent) in Romania (IV) (Boehringer Ingelheim Pipeline, May 2022)